SAN DIEGO, CA — August 5, 2026 — Leads & Copy — Dermata Therapeutics, Inc. (NASDAQ:DRMA), a science-driven leader in dermatologic solutions, announced that its first direct-to-consumer skincare product, Tome Foundational Treatment, is slated for launch on August 25, 2026. Individuals on the waitlist will receive early access to pre-orders. This launch marks a significant step in Dermata’s strategic shift towards becoming a consumer-focused, revenue-generating skincare company.
The Tome brand is conceptualized to deliver professional-grade skincare solutions directly to consumers, addressing a growing market demand for accessible products that integrate the efficacy of professional treatments into everyday routines. The Tome Foundational Treatment is a once-weekly skin renewal product designed to promote smoother, brighter, and healthier-looking skin.
A key component of the Foundational Treatment is the Company’s proprietary Bioneedle™ technology, which utilizes wild-harvested freshwater sponge to facilitate a comprehensive skin resurfacing experience. The set will include four once-weekly treatments, priced at $178, with each treatment costing approximately $45. Each kit contains a cup of Bioneedle powder, an Activator solution tube, and an application brush. Consumers will mix the components before applying as a mask to ensure uniform distribution and maximum potency.
This Foundational Treatment is the first in a planned series of consumer skincare products from Dermata under the Tome brand. Gerry Proehl, Chief Executive Officer of Dermata Therapeutics, stated, “The upcoming commercial launch of our Tome Foundational Treatment is a defining moment for Dermata, our investors, and consumers.” He added, “Last year we announced a strategic pivot from developing prescription products to focusing on direct-to-consumer skincare. We believe consumers are increasingly looking for effective, science-backed skincare that fits seamlessly into their routine, and Tome Foundational Treatment was designed with that goal in mind. This product will establish the commercial foundation for our Tome brand, and we believe will demonstrate the versatility of our Bioneedle platform.”
Dermata anticipates that the Tome Foundational Treatment will offer consumers an at-home alternative to in-office procedures such as microneedling, chemical peels, and laser treatments. The company notes a rise in consumer awareness and demand for aesthetic treatments, largely influenced by social media, leading to a search for accessible products that deliver visible results.
Tome’s product development philosophy combines naturally derived ingredients with contemporary scientific research to create skincare treatments aimed at simplifying routines while addressing common skin quality issues. Dermata believes this approach positions Tome to bridge the gap between conventional at-home skincare and professional aesthetic procedures.
Tome, a skincare brand from Dermata, integrates a timeless ingredient with modern science, offering professional-grade skincare powered by natural and safe components. Its signature ingredient, Bioneedle™, is derived from exclusively sourced, wild-harvested Spongilla lacustris, a freshwater sponge. The brand’s once-weekly Foundational Treatment brings a potent skin resurfacing experience to the home. More information is available at www.tomeskincare.com.
Dermata Therapeutics is a science-driven dermatology company dedicated to developing innovative skincare solutions supported by scientific research. Through its consumer brand, Tome, Dermata is expanding its offerings to deliver clinically tested skincare products directly to consumers. The company is headquartered in San Diego, California. Further details can be found at www.dermatarx.com.
Source: Dermata Therapeutics, Inc.
